Landos Biopharma Inc reports results for the quarter ended in September - Earnings Summary

Landos Biopharma

14/11/2022 14:31

* Landos Biopharma Inc  LABP.OQ  reported a quarterly
adjusted
loss of 20 cents​​ per share for the quarter ended in September.
The mean expectation of three analysts for the quarter was for a
loss of 28 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Landos Biopharma Inc's reported EPS for the quarter was a
loss
of 20 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Landos Biopharma Inc shares had fallen by 58.6% this
quarter and
lost 94.4% so far this year.
    * The company reported a quarterly loss of $7.9 million.
    * Wall Street's median 12-month price target for Landos
Biopharma
Inc is $2.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 02:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.28          -0.20          Beat
 Jun. 30 2022      -0.36          -0.28          Beat
 Mar. 31 2022      -0.35          -0.37          Missed
 Dec. 31 2021      -0.33